Literature DB >> 201534

Combination chemotherapy of 6-thioguanine with various antitumor agents against murine leukemia L-1210.

S Fujimoto, J Inagaki, N Horikoshi, A Hoshino.   

Abstract

Antitumor activity of 6-thioguanine against L-1210 leukemia was studied in combination with various antitumor agents in clinical stages, such as mitomycin-C, carbazilquinone, cyclophosphamide, 3,3'-dimesyloxydipropylamine tosylate (864T), 4-hydroperoxyisophosphamide, and 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chlorethyl)-1-nitrosourea hydrochloride (ACNU). The combination treatments with 6-thioguanine and each of six agents, especially with ACNU, showed a distinct therapeutic effect against the early L-1210 leukemia at dosage levels not producing any significant antitumor activity with each agent alone (ip-ip). The excellent antitumor activity of the combination of 6-thioguanine with ACNU was also proved in various sites of tumor inoculation and routes of drug administration systems, i.e., ip-iv, iv-ip, and iv-iv systems. Moreover, the effectiveness of the combination of these two drugs was clearly shown against advanced L-1210 leukemia which was refractory to each agent alone.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 201534

Source DB:  PubMed          Journal:  Gan        ISSN: 0016-450X


  3 in total

1.  Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas.

Authors:  D C Smith; N A Vick; D L Trump; H S Friedman; A H Friedman; J Purvis; A Gauspari; S C Schold
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Experimental and clinical effect of ACNU in Japan with emphasis on small-cell carcinoma of the lung.

Authors:  N Saijo; H Niitani
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

3.  Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts.

Authors:  A M Wang; G B Elion; H S Friedman; W J Bodell; D D Bigner; S C Schold
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.